6 Key Considerations for a Biological Product’s Journey from R&D to Market
21 September 2026 A product may shine in one season’s trials and disappoint in the next. The product wavers in efficacy because the crop, soil, and agronomic program were different. The lesson is that nothing about biological performance can be assumed.
Biology is context dependent. Consistency must be built into the product, from the raw material and manufacturing process through to field use. Here are six points to consider for going from product development to a market launch.
1. Know What You Are Making
Natural extracts and other complex biological products carry inherent variability. Raw materials change with the source, season, harvest conditions, and processing, so quality control starts well before the finished batch is tested.
R&D needs to establish which constituents, combinations, or structural features are associated with bioactivity and how changes in composition affect function. A company does not need to identify every molecule before launch, but it does need a reliable link between composition and performance. That should guide raw material selection, process controls, product specifications, and batch release.
Otherwise, the material used in early R&D may not match what is later trialed or supplied to the grower. In that case, you have validated a batch, not a product.
This work is expensive but not optional. If you cannot define an active product and make it repeatedly, it is difficult to explain, sell, or scale.
2. Make the Trial Answer the Commercial Question
Field trials are noisy. Soil, variety, weather, crop stage, application timing, fertility, and the surrounding spray program can all affect the result. That makes a genuine product effect hard and expensive to pick out.
Start with the claim. A formal trial needs the right controls, enough replication, and a measurement that matches the promise. For quality, measure marketable quality. For nutrient-use efficiency, test performance under a defined nutrient program. For resilience, characterize the stress and measure yield loss against an untreated control.
One result is not enough. The question is whether the response repeats under the conditions in which the product will be sold.
A commercial demonstration serves a different purpose. An untreated strip does not replace a replicated trial, but it gives the grower a direct comparison. In a mild year, there may be little difference because there was little stress to mitigate. In a bad year, that comparison makes avoided loss visible.
3. Choose a Problem the Grower Can See
Do not launch across 10 crops and a long list of loosely defined benefits because the product might work in all of them. Start with a crop, growth stage, and problem where the result is tangible and the grower can put a value on it.
Knowing how the product works helps you choose the timing, conditions, and measurements most likely to reveal its value. It does not replace field evidence, but it makes the trials more useful and the product easier to explain.
4. Let Regulation Shape the Claim
Regulation shapes the claim before marketing does. In the EU, the Fertilizing Products Regulation defines biostimulants by what they do: improving nutrient-use efficiency, tolerance to abiotic stress, or crop quality.
Other markets take their own approaches, but designing and testing against the most stringent standard is usually more efficient than treating every market as a separate exercise.
5. Who Pays for the Proof?
Before you launch, decide whether you are building a branded product or supplying an ingredient.
The branded route gives you control of the claims and customer relationship, but the margin has to pay for local trials, technical support, training, and distributor activation. The ingredient route carries lower overheads and usually lower margins, with the risk that it can be replaced.
Co-branding can sit between the two where the supplier’s science and name carry enough value to be recognized on the final product. It can reduce substitution risk but not remove it.
What does not work is the muddle between the models: ingredient margins carrying brand ambitions or premium claims without the evidence budget to support them. Weak claims also make the next biological harder to sell.
The proof gap is real. It can take two or three seasons to build credible market data, followed by another season or two of distributor validation. A season is a season; you cannot sprint through it. Parallel trials, a beachhead crop, and independent third-party work can shorten the runway but not remove the evidence bill.
6. Assume a Buyer Will Audit It
On a recent crop input acquisition, one diligent question captured the issue: Is the product being sold the same product that generated the data?
Buyers check the whole chain: raw material security, production controls, specifications, trial quality, regulatory status, and channel economics.
A launch does not begin when the marketing campaign starts. It begins with knowing what is in the product, making it consistently, testing it in the right conditions, and giving the grower a result they can see and value. In a crowded market, that repeatability and the ability to explain it will set the product apart.
Measure, check, talk to the grower, and never assume.
Get The Newsletter Today!
